A 42-year-old woman undergoes renal transplantation for end-stage renal disease. She is initiated on a triple immunosuppressive regimen consisting of tacrolimus, mycophenolate mofetil (MMF), and prednisolone. At 6 weeks post-transplant, she develops severe diarrhea (8–10 stools/day), abdominal cramping, and weight loss of 3 kg. Serum creatinine remains stable at 1.2 mg/dL. Stool culture and C. difficile toxin are negative. Which immunosuppressant is most likely responsible for her gastrointestinal symptoms, and what is the recommended management?

Explanation

## Clinical Scenario Analysis The patient presents with severe diarrhea 6 weeks post-transplant while on triple therapy. The key clinical clues are: - **Timing**: occurs early post-transplant (6 weeks) - **Stable graft function**: creatinine normal, ruling out acute rejection - **Negative infectious workup**: excludes C. difficile and bacterial causes - **Gastrointestinal-specific toxicity**: diarrhea with cramping and weight loss ## Mechanism of MMF-Induced Diarrhea **Key Point:** Mycophenolate mofetil (MMF) is metabolized to mycophenolic acid (MPA), which inhibits inosine monophosphate dehydrogenase (IMPDH) in T and B lymphocytes. However, MPA also has effects on the gastrointestinal tract. **High-Yield:** MMF causes dose-dependent diarrhea in 10–25% of transplant recipients, typically occurring within the first 3 months. The mechanism involves: 1. Direct irritation of the GI mucosa by MPA and its metabolites 2. Altered gut flora and increased bacterial overgrowth 3. Increased intestinal motility ## Differential Diagnosis of Post-Transplant Diarrhea | Agent | Mechanism | Frequency | Management | |-------|-----------|-----------|-------------| | **MMF** | Direct mucosal irritation, IMPDH inhibition in gut | 10–25% | Dose reduction, switch to azathioprine or enteric-coated formulation | | Tacrolimus | Neurotoxicity, not primary GI effect | Rare | Switch to cyclosporine (not first-line for diarrhea) | | Prednisolone | Immunosuppression, not direct diarrhea | Rare | Increasing dose worsens diarrhea | | Cyclosporine | Gingival hyperplasia, tremor, not diarrhea | Rare | Not indicated | ## Management Strategy **Clinical Pearl:** When MMF-related diarrhea occurs: 1. **First-line**: Reduce MMF dose (e.g., from 1 g twice daily to 500 mg twice daily) 2. **Second-line**: Switch to enteric-coated mycophenolate sodium (EC-MPS), which delays absorption and reduces GI toxicity 3. **Third-line**: Replace with azathioprine (1–2 mg/kg/day), which has a lower GI side-effect profile **Tip:** Do NOT increase prednisolone or switch tacrolimus for MMF-related diarrhea — these agents are not the cause and will not resolve the symptom. ## Why Other Options Are Incorrect - **Tacrolimus toxicity** typically manifests as tremor, neurotoxicity, or hyperglycemia, not diarrhea - **Prednisolone** at higher doses may worsen diarrhea by promoting bacterial overgrowth - **Proton pump inhibitors** do not address the underlying mechanism of MMF-induced diarrhea [cite:KD Tripathi 8e Ch 72]